EDIT Editas Medicine Inc

Price (delayed)

$38.16

Market cap

$2.6B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.59

Enterprise value

$2.3B

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a ...

Highlights
Editas Medicine's gross profit has soared by 149% YoY but it has decreased by 11% from the previous quarter
The revenue has soared by 149% year-on-year but it has declined by 11% since the previous quarter
Editas Medicine's net income has decreased by 26% YoY and by 23% QoQ
EDIT's EPS is down by 17% since the previous quarter and by 3.2% year-on-year

Key stats

What are the main financial stats of EDIT
Market
Shares outstanding
68.26M
Market cap
$2.6B
Enterprise value
$2.3B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.22
Price to sales (P/S)
31.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
28.31
Earnings
Revenue
$81.14M
EBIT
-$167.4M
EBITDA
-$162.76M
Free cash flow
-$189.3M
Per share
EPS
-$2.59
Free cash flow per share
-$2.79
Book value per share
$9.04
Revenue per share
$1.2
TBVPS
$11.14
Balance sheet
Total assets
$755.88M
Total liabilities
$142.52M
Debt
$30.26M
Equity
$613.36M
Working capital
$550.28M
Liquidity
Debt to equity
0.05
Current ratio
9.34
Quick ratio
9.25
Net debt/EBITDA
1.89
Margins
EBITDA margin
-200.6%
Gross margin
100%
Net margin
-205.4%
Operating margin
-208.5%
Efficiency
Return on assets
-24.6%
Return on equity
-32%
Return on invested capital
-45.8%
Return on capital employed
-24.3%
Return on sales
-206.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EDIT stock price

How has the Editas Medicine stock price performed over time
Intraday
0.9%
1 week
-0.31%
1 month
-35%
1 year
16.48%
YTD
-45.57%
QTD
-7.11%

Financial performance

How have Editas Medicine's revenue and profit performed over time
Revenue
$81.14M
Gross profit
$81.14M
Operating income
-$169.17M
Net income
-$166.66M
Gross margin
100%
Net margin
-205.4%
Editas Medicine's gross profit has soared by 149% YoY but it has decreased by 11% from the previous quarter
The revenue has soared by 149% year-on-year but it has declined by 11% since the previous quarter
EDIT's operating margin has surged by 55% year-on-year but it is down by 31% since the previous quarter
The net margin has grown by 49% YoY but it has contracted by 39% from the previous quarter

Growth

What is Editas Medicine's growth rate over time

Valuation

What is Editas Medicine stock price valuation
P/E
N/A
P/B
4.22
P/S
31.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
28.31
EDIT's EPS is down by 17% since the previous quarter and by 3.2% year-on-year
EDIT's equity is up by 44% year-on-year but it is down by 3.9% since the previous quarter
EDIT's P/B is 35% below its last 4 quarters average of 6.4 and 25% below its 5-year quarterly average of 5.6
The revenue has soared by 149% year-on-year but it has declined by 11% since the previous quarter
The P/S is 52% less than the 5-year quarterly average of 66.1 and 11% less than the last 4 quarters average of 35.5

Efficiency

How efficient is Editas Medicine business performance
EDIT's return on sales has surged by 51% year-on-year but it is down by 39% since the previous quarter
EDIT's return on invested capital is up by 35% year-on-year
The ROE has increased by 31% YoY but it has decreased by 13% from the previous quarter
Editas Medicine's ROA has decreased by 19% from the previous quarter but it has increased by 7% YoY

Dividends

What is EDIT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EDIT.

Financial health

How did Editas Medicine financials performed over time
EDIT's total liabilities is down by 38% year-on-year
EDIT's total assets is up by 15% YoY but it is down by 3.1% QoQ
The debt is 95% less than the equity
EDIT's equity is up by 44% year-on-year but it is down by 3.9% since the previous quarter
The company's debt to equity fell by 29% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.